GET DAILY SIGNALSAtossa Therapeutics (ATOS): Analyst Targets Point to a Potential +1,000% Upside
Key Takeaways
- The central target of $25 is the arithmetic mean of the two current analyst price targets on Atossa Therapeutics, Inc. (ATOS), with both H.C. Wainwright and Ascendiant Capital carrying Buy ratings.
- At a latest verified price of roughly $2.10 per share, reaching $25 would require an upside of more than 1,000%, an extremely large move for a clinical-stage biotech.
- The two covering analysts are closely aligned, with targets in a narrow band from about $24 to $25; both were adjusted after Atossa's 1-for-15 reverse stock split in early 2026.
- The strongest support comes from clinical progress on lead candidate (Z)-endoxifen, including FDA Rare Pediatric Disease and Orphan Drug designations in Duchenne muscular dystrophy.
- The biggest risks are a tiny market capitalization, ongoing cash burn, dilutive financing, and binary clinical-trial outcomes common to micro-cap biotechs.
- For more context on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
Understanding the Analyst Consensus
Atossa Therapeutics is a Seattle-based, clinical-stage biopharmaceutical company focused on hormone-driven cancers, with its lead candidate being oral (Z)-endoxifen, a selective estrogen receptor modulator and degrader. Coverage is thin: two sell-side firms currently publish price targets, both at Buy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and set a $25 target in March 2026, adjusting it from $7 to reflect the company's 1-for-15 reverse stock split. Ascendiant Capital analyst Edward Woo most recently maintained a Buy and raised the target to $25 from $24 in October 2026. Because the reverse split makes pre-split targets incomparable, only these post-split figures are used here. The calculated mean is $25, with a range spanning roughly $24 to $25, so there is little dispersion between the two firms.
This is not an official published consensus; it is a simple average of two attributed targets. A two-analyst sample offers a narrow read, and both firms are decidedly bullish on the pipeline, particularly the (Z)-endoxifen program.
Where the Stock Stands Today
The stock trades near $2.10, well below its 52-week range of roughly $1.70 to $14.85 and down sharply after the early-2026 reverse split. Reaching $25 would require a gain exceeding 1,000%, which by any standard is a very large move and not a modest or routine re-rating.
The only realistic path to such a level involves successful late-stage clinical data, regulatory milestones, and a fundamental re-rating of a company whose market capitalization is only around $20 million to $22 million. That is the nature of binary biotech: the valuation can expand dramatically on a single positive catalyst or compress on a setback. No timing is implied.
Factors That Could Drive the Stock Higher
The clearest support is clinical and regulatory progress on (Z)-endoxifen. The company has secured two FDA designations for the drug in Duchenne muscular dystrophy (DMD): Rare Pediatric Disease designation and Orphan Drug Designation, which can support an expedited review path and market exclusivity if approved. Atossa has also received FDA clearance to proceed with a study of (Z)-endoxifen in estrogen receptor-positive, HER2-negative metastatic breast cancer, and has presented preclinical DMD data showing improved muscle strength in animal models.
A stapled contingent value right (CVR), capped at $50 million and tied to a potential rare pediatric disease priority review voucher, adds an optionality component beyond the core pipeline. Both covering analysts cite the breadth of the program and potential catalysts over the next year as reasons for their Buy ratings.
Key Risks to Consider
The obstacles are substantial. Atossa is a micro-cap with roughly 16 employees and a small cash base relative to the cost of Phase 2 development, forcing recurring equity raises. The company completed dilutive registered direct offerings in 2026, and further dilution would pressure the share price even if the science advances.
Clinical-stage oncology and rare-disease programs carry binary risk: a failed or inconclusive trial, a regulatory delay, or an inability to fund continued development could reset expectations sharply. The stock's decline from its 52-week high illustrates how quickly sentiment can shift in thinly covered, low-liquidity names. The $25 target itself rests on the assumption that pipeline milestones are met and that the company can access capital on acceptable terms.
Technical Picture
The post-split chart offers limited durable technical structure, but two reference points stand out: the 52-week low near $1.70 acts as a psychological and structural floor in recent trading, while the roughly $14.85 high marks the upper boundary of post-split trading. The shares sit far closer to the low, and the $25 target lies well above any price the stock has printed since the split, meaning there is no nearby technical precedent to anchor such a move.
What to Watch Going Forward
Analyst price targets typically reflect a roughly 12-month research horizon, though neither covering firm has published a materially different timeframe. The most important upcoming items are clinical data readouts for (Z)-endoxifen across breast cancer and rare-disease indications, additional regulatory designations or clearances, and any new financing announcements.
Investors should also watch cash runway disclosures in quarterly filings, updates on the CVR and priority review voucher process, and any changes to the two-firm analyst coverage. Given the binary nature of the pipeline, data events matter more than ordinary quarterly financials. From what I see, monitoring these catalysts closely is essential.
Using AI for Systematic Monitoring
For traders who prefer a systematic lens, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening allows. For a high-volatility micro-cap like Atossa, such automated monitoring can complement fundamental research by flagging momentum shifts as they develop. I find it particularly useful for staying on top of names with limited analyst coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ATOS shows an upward move is likely
ATOS's Aroon Indicator triggered a bullish signal on October 26, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 148 similar instances where the Aroon Indicator showed a similar pattern. In 119 of the 148 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in 184 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATOS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 25 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATOS as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ATOS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 46 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ATOS moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ATOS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.789) is normal, around the industry mean (3.498). P/E Ratio (-0.488) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. ATOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of products for breast cancer
Industry Biotechnology
Advertisement